



Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

I, **Stefan Strasser**

Organisation/Company:

Country:

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

1.1 Employment

No interest declared

1.2 Consultancy

No interest declared

1.3 Strategic advisory role

No interest declared

1.4 Financial interests

No interest declared

1.5 Principal investigator

No interest declared

1.6 Investigator

No interest declared

1.7 Grant / Funding to organisation /institution

No interest declared

1.8 Close family member interest

No interest declared

1.9 Repurposing of a medicinal product

No interest declared

1.10 Any other interests or facts

Member of study team (study coordinator, study nurse) for the following commercial trials:

_ 2008_002231_32

A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST_TRANSPLANT) AND MMF WITH OR WITHOUT A MONOCLONAL ANTI_IL2R ANTIBODY (BASILIXIMAB)

_ 2010_019639_37

A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF_BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS.

_ Medical Device (No EudraCT)

Prospective Multi_Center Randomized Post Market Study to Evaluate the PleuraSeal Sealant System as Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy
Member of study team (study coordinator, data manager, statistical advisor) for the following academic trials:

_ 2004_000048_KP (before implementation of 2011/20/EC)

INVESTIGATING CAMPATH_1H AS INDUCTION AGENT IN PATIENTS WITH RENAL TRANSPLANTATION

_ 2005_005362_36

A PROSPECTIVE RANDOMISED, OPEN_LABELLED, TRIAL COMPARING SIROLIMUS_CONTAINING VERSUS mTOR_INHIBITOR_FREE IMMUNOSUPPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA

_ 2006_000845_21

AN OPEN_LABEL RANDOMIZED; PROSPECTIVE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CAMPATH_1H AS AN INDUCTION AGENT IN COMBINATION WITH TACROLIMUS MONOTHERAPY COMPARED TO SHORT_COURSE ATG_INDUCION IN COMBINATION WITH TACROLIMUS; MYCOPHENOLATE MOFETIL AND SHORT_TERM STEROIDS APPLICATION IN DE NOVO SPK TRANSPLANTED DIABETIC PATIENTS

Other clinical trials did not include medicinal products or me.

I confirm that in none of the trials I had the role of (principal) investigator or took any patient_related decisions.

1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No interest declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party ¹ any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.

Full Name:	Stefan Strasser
Date:	2023-03-22

For definitions of activities etc, refer to the policy on handling of competing interests.